U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07787208) titled 'A Study of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid Tumors' on Aug. 18.
Brief Summary: This study is to evaluate the tolerability and safety of ONO-7429 in participants with unresectable advanced or recurrent solid tumors.
Study Start Date: June 19
Study Type: INTERVENTIONAL
Condition:
Solid Tumors
Intervention:
DRUG: ONO-7429
Specified dose on specified days
Recruitment Status: RECRUITING
Sponsor: Ono Pharmaceutical Co., Ltd.
Disclaimer: Curated by HT Syndication....